The International Hyperhidrosis Society was founded in 2003 by a group of dedicated physicians and medical professionals with a commitment to scientific rigor in hyperhidrosis and related fields. As part of that commitment, we keep an extensive inventory of published scientific literature relevant to hyperhidrosis and share it with you, here. We believe it's vital to review published clinical data whenever discussing or reporting on health and hyperhidrosis and we strongly encourage product and treatment development teams to conduct rigorous testing and to espouse only that which can be validated.
Below you will find chronological links to articles, posters, and study data representing the most current peer-reviewed medical and scientific information available on the physiology, treatment, and effects of hyperhidrosis. New data will be posted as it becomes available. Use this rich library of research to inform your decisions and perceptions.
Are you working on research in hyperhidrosis? We can help in many ways!
Want to provide a grant to support hyperhidrosis research? Just send an email to our Executive Director, Lisa J. Pieretti via our Contact Us form.
And, as always, your donations are vital to our continued, collective work toward better care, improved lives, and greater understanding.
We do our best to scour all publications and post hyperhidrosis research here, but if we have missed something, please let us know. We will be happy to include it!
Glaser DA, Hebert A, Pieretti L, Pariser D. Understanding Patient Experience with Hyperhidrosis: A National Survey of 1,985 Patients. Journal fo Drugs in Dermatology. 2018 17(4):392-396
Glaser D et al. Open-label study evaluating long-term safety of topical glycopyrronium tosylate (GT) in patients with primary axillary hyperhidrosis (ARIDO). Presented at the 76th Annual Meeting of the American Academy of Dermatology February 2018.
Hebert A et al. Glycopyrronium tosylate for the treatment of primary axillary hyperhidrosis: pediatric subgroup analyses from the ATMOS-1 and ATMOS-2 phase 3 randomized controlled trials. Presented at the 76th Annual Meeting of the American Academy of Dermatology February 2018.
Pariser D et al. Topical glycopyrronium tosylate (DRM04) for the treatment of primary axillary hyperhidrosis: pooled results from the ATMOS-1 and ATMOS-2 phase 3 randomized controlled trials. Presented at the 76th Annual Meeting of the American Academy of Dermatology February 2018.
Pariser D et al. Glycopyrronium tosylate for the treatment of primary axillary hyperhidrosis: prior treatment analyses from the ATMOS-1 and ATMOS-2 phase 3 randomized controlled trials. Presented at the 76th Annual Meeting of the American Academy of Dermatology February 2018.
Kamudoni P, Mueller B, Halford J, Schouveller A, Stacey B, Salek MS. The impact of hyperhidrosis on patients' daily life and quality of life: a qualitative investigation. Health and Quality of Life Outcomes. 2017 15:121.
Glaser D et al. Open-label study (ARIDO) evaluating long-term safety of topical glycopyrronium tosylate (GT) in patients with primary axillary hyperhidrosis. Presented at the 36th Fall Clinical Dermatology Conference October 2017.Conference October 2017.
Grabell D, Hebert A. Current and Emerging Medical Therapies for Primary Hyperhidrosis. Dermatol Ther (Heidelb). 2017 Mar; 7(1): 25–36.
Hebert A, Glaser DA, Ballard A, Pieretti L, Trindade de Almeida A, Pariser D. Prevalence of primary focal hyperhidrosis among teens 12-17 in US Population. Abstract (5192) presented at American Academy of Dermatology March 2017, Late-Breaking Research: Clinical Studies/Pediatric (F072).
Pariser D, Krishnaraja J, Tremblay T, Rubison M, Love T, McGraw B. Randomized, Placebo- and Active-Controlled Crossover Study of the Safety and Efficacy THVD-102, a Fixed-dose Combination of Oxybutynin and Pilocarpine, in Subjects with Primary Focal Hyperhidrosis. Journal of Drugs in Dermatology 2017 Feb 1;16(2): 127-132.
Pariser D, Hebert A, Drew J, Quiring J, Glaser D. Patient-reported outcomes from two randomized, double-blind, vehicle-controlled phase 3 trials in axillary hyperhidrosis (ATMOS-1 & ATMOS-2). Presented at the 26th European Academy of Dermatology and Venereology Congress September 2017.outcomes from two randomized, double-blind, vehicle-controlled phase 3 trials in axillary hyperhidrosis (ATMOS-1 & ATMOS-2). Presented at the 26th European Academy of Dermatology and Venereology Congress September 2017.
Pariser D et al. DRM04 for the treatment of primary axillary hyperhidrosis: primary results from the ATMOS-1 and ATMOS-2 phase 3 randomized controlled trials. Poster 4834 presented at the 75th Annual Meeting of the American Academy of Dermatology March 2017.hyperhidrosis: primary results from the ATMOS-1 and ATMOS-2 phase 3 randomized controlled trials. Poster 4834 presented at the 75th Annual Meeting of the American Academy of Dermatology March 2017.
Dagash H, McCaffery S, Mellor K, Roycroft A, Helbling I. Tap water iontophoresis in the treatment of pediatric hyperhidrosis. J Pediatr Surg. 2017 Feb;52(2):309-312.
Hsu TH, Chen YT, Tu YK, Li CN. A systematic review of microwave-based therapy for axillary hyperhidrosis. J Cosmet Laser Ther. 2017 Mar 10. doi: 10.1080/14764172.2017.1303168.
Millan-Cayetano JF, et al. Initial study of transdermal oxybutynin for treating hyperhidrosis. J Dermatol doi: 10.1111/1346-8138.13748. Published online January 20, 2017.
Bahar R, Zhou P, Liu Y, Huang Y, Phillips A, Lee T, et al. The prevalence of anxiety and depression in patients with or without hyperhidrosis (HH). J Am Acad Dermatol 75:6 (2016): 1126-1133.
del Boz J et al. Individualized Dosing of Oral Oxybutynin for the Treatment of Primary Focal Hyperhidrosis in Children and Teenagers. Pediatr Dermatol (2016) 33: 327–331.
Doolittle J, Walker P, Mills T, et al. Hyperhidrosis: an update on prevalence and severity in the United States. Arch Dermatol Res doi: 10.1007/s00403-016-1697-9. Published online October 15, 2016.
Cramer DW, Vitonis AF, Terry KL, Welch WR, et al. The association between talc use and ovarian cancer: a retrospective case-control study in two US states. Epidemiology. 2016 May;27(3):334-46.
Cruddas L, Baker DM. Treatment of primary hyperhidrosis with oral anticholinergic medications: a systematic review. J Eur Acad Dermatol Venereol. 2016 Dec 15. doi: 10.1111/jdv.14081.
Glaser D, Ballard A, Hunt N, Pieretti L & Pariser D. Prevalence of multifocal primary hyperhidrosis and symptom severity over time: results of a targeted survey. Dermatol Surg 42:12 (2016): 1347-1353.
Hansen CR, Godfrey B. Residual Limb Hyperhidrosis Managed by Botulinum Toxin Injections, Enhanced by the Iodine-Starch Test: A Case Report. American Academy of Physical Medicine and Rehabilitation. 2016 Oct 22. pii: S1934-1482(16)31056-5.
Ismail D, Madhwapathi V, Ladoyanni E. Focal Hyperhidrosis Associated with Recurrent Urinary Tract Infections. Case Reports in Dermatological Medicine. 2016;2016:3842984.
Muthusamy A, Gajendran R, Ponnan S, Thangavel D, Rangan V. A Study on the Impact of Hyperhidrosis on the Quality of Life among College Students. Journal of Clinical and Diagnostic Research: JCDR. 2016;10(6):CC08-CC10.
Overwhelming foot odor. J Fam Pract. 2016 January;65(1)
Owen K. Excessive Sweating: Are Patients Suffering Unnecessarily? The Journal for Nurse Practitioners, January 2016, Volume 12, Issue 1, 35–40
Liu Y, Bahar R, Kalia S, Huang RY, Phillips A, Su M, et al. Hyperhidrosis prevalence and demographical characteristics in dermatology outpatients in Shanghai and Vancouver. PLoS One doi: 10.1371/journal.pone.0153719. Published online April 22, 2016.
Pariser D et al. DRM04 for the treatment of axillary hyperhidrosis: primary results from the ATMOS-1 and ATMOS-2 phase 3 randomized controlled trials. Late Breaking News D3T01.1 presented at the 25th European Academy of Dermatology and Venereology Congress October 201primary results from the ATMOS-1 and ATMOS-2 phase 3 randomized controlled trials. Late Breaking News D3T01.1 presented at the 25th European Academy of Dermatology and Venereology Congress October 201
Risacher SL, McDonald BC, Tallman EF, et al. Association between anticholinergic medication use and cognition, brain metabolism, and brain atrophy in cognitively normal adults. JAMA Neurol. doi:10.1001/jamaneurol.2016.0508. Published online April 18, 2016.
Shayesteh A, Janlert U, Brulin C, Boman J, Nylander E. Prevalence and characteristics of hyperhidrosis in Sweden: a cross-sectional study inthe general population. Dermatology doi: 10.1159/000448032.
Singh S, Kaur S, Wilson P. Early experience with endoscopic lumbar sympathectomy for plantar hyperhidrosis. Asian J Endosc Surg. 2016 May;9(2):128-34.
Lima SO et al. Research of primary hyperhidrosis in students of medicine of the State of Sergipe, Brazil. Anais Brasileiros de Dermatologia. 2015;90(5):661-665.
Hansen C et al. Incidence, severity, and impact of hyperhidrosis in people with lower-limb amputation. J Rehabil Res Dev. 2015;52(1):31–40.
Ma C, Sivamani RK. Acupuncture as a Treatment Modality in Dermatology: A Systematic Review. J Altern Complement Med. 2015 Sep;21(9):520-9.
Gray, Shelly L PharmD, MS, et al. Cumulative use of strong anticholingerics and incident of dementia. JAMA Intern Med doi: 10.1001/jamainternmed.2014.7663. Published online January 26, 2015.
Campbell NL, Boustani MA. Adverse cognitive effects of medications. Turning attention to reversibility. Invited commentary. JAMA Intern Med doi: 10.1001/jamainternmed.2014.7667.
Nicholas R, Quddas A, Baker DM. Treatment of Primary Craniofacial Hyperhidrosis: A Systemic Review. Am J Clin Dermatol. 2015 Oct;16(5):361-70. doi: 10.1007/s40257-015-0136-6.
Schollhammer M, Brenaut E, Menard-Andivot N, Pillette-Delarue M, et al. (2015). Oxybutynin as a treatment for generalized hyperhidrosis: a randomized, placebo-controlled trial. British Journal of Dermatology, 173: 1163-1168. doi: 10.1111/bjd.13973
Bohaty, Benjamin R. MD & Hebert, Adelaide A. MD. Special considerations for children with hyperhidrosis. Dermatologic Clinics 32:4 (2014): 477-484.
Caplin D, Austin J. Clinical evaluation and quantitative analysis of axillary hyperhidrosis treated with a unique targeted laser energy delivery method with 1-year follow up. J Drugs Dermatol 13:4 (2014): 449-456.
Hamm, Henning MD. Impact of hyperhidrosis on quality of life and its assessment. Dermatologic Clinics 32:4 (2014): 467-476.
Laniosz, V, et al. Dermatologic manifestations of fibromyalgia. Clin Rheumatol doi: 10.1007/s10067-014-2488-3. Published online January 14, 2014.
Klar, Joakim, et al. Abolished InsP3R2 function inhibits sweat secretion in both humans and mice. J Clin Invest doi: 10.1172/JCI70720. Published online October 20, 2014.
Moraites, Eleni MD, et al. Incidence and prevalence of hyperhidrosis. Dermatologic Clinics 32:4 (2014): 457-465.
Nestor MS, Park H. Safety and efficacy of micro-focused ultrasound plus visualization for the treatment of axillary hyperhidrosis. J ClinAesthet Dermatol 7:4 (2014): 14-21.
Pariser D, Ballard A. Topical therapies in hyperhidrosis care. Dermatologic Clinics 32:4 (2014): 485-490.
Pariser D, Ballard A. Iontophoresis for palmar and plantar hyperhidrosis. Dermatologic Clinics 32:4 (2014): 491-494.
Trindade de Almeida A, Montagner S. Botulinum toxin for axillary hyperhidrosis. Dermatologic Clinics 32:4 (2014): 495-504.
Weinberg T et al. Botulinum neurotoxin treatment of palmar and plantar hyperhidrosis. Dermatologic Clinics 32:4 (2014): 505-515.
Glaser DA, Galperin TA. Botulinum toxin for hyperhidrosis of areas other than the axillae and palms/soles. Dermatologic Clinics 32:4 (2014): 517-525.
Glaser DA. Oral medications. Dermatologic Clinics 32:4 (2014): 527-532.
Glaser DA, Galperin TA. Local procedural approaches for axillary hyperhidrosis. Dermatologic Clinics 32:4 (2014): 533-540.
Moraites E et al. Endoscopic thoracic sympathectomy. Dermatologic Clinics 32:4 (2014): 541-548.
Glaser, DA, Galperin T. Managing hyperhidrosis: emerging therapies. Dermatologic Clinics 32:4 (2014): 549-553.
Pieretti L. Resources for hyperhidrosis sufferers, patients, and health care providers. Dermatologic Clinics 32:4 (2014): 555-564.
Pariser DM. Incorporating diagnosis and treatment of hyperhidrosis into clinical practice. Dermatologic Clinics 32:4 (2014): 565-574.
Mela S, Whitworth DE. The fist bump: a more hygienic alternative to the handshake. American Journal of Infection Control 42:8 (2014): 916-917.
Sklansky M et al. Banning the handshake from the health care setting. JAMA 311:24 (2014): 2477-2478.
Boschert S. Laser therapy improved severe hyperhidrosis. Dermatology News, 30 April 2014.
Pinson I et al. Non-invasive short-wave guided radiofrequency device for long-term sweat reduction in patients with primary axillary hyperhidrosis: a preliminary study, presented at the 34 ASLMS Annual Conference, April 4-6, 2014, Phoenix, AZ.
Laniosz V, Wetter DA, Godar DA. Dermatologic manifestations of fibromyalgia. Clin Rheumatol 2014 Jul;33(7):1009-13.
Augustin M, Radtke MA, Herberger K, Kornek T, Heigel H & Schaefer I. Prevalence and disease burden of hyperhidrosis in the adult population. Dermatology 227 (2013): 10-13.
Terry KL, Karageorgi S, Shvetsov YB, Merritt MA, et al. Genital powder use and risk of ovarian cancer: A pooled analysis of 8,525 cases and 9,859 controls. Cancer Prev Res (Phila). 2013 Aug;6(80): 811-21.
de Menezes LR. Visual scale for the quantification of hyperhidrosis. J. bras. Pneumol 39:4 (2013).
Fatemi A. Apparatus for the treatment of hyperhidrosis. Patent EP 2645954 A1. 9 October 2013.
Fujimoto T, Kawahara K, Yokozeki H. Epidemiological study and considerations of primary focal hyperhidrosis in Japan: fromquestionnaire analysis. J Dermatol 40:11 (2013): 886-890.
Patakfalvi L, Benohanian A. Treatment of palmar hyperhidrosis with needle-free injection of botulinum toxin A. Arch Dermatol Res doi: 10.1007/s00403-013-1425-7
Gordon JRS, Hill SE. Update on pediatric hyperhidrosis. Dermatologic Therapy 26 (2013): 452-461.
Lee S et al. The efficacy of a microwave device for treating axillary hyperhidrosis and osmidrosis in Asians: a preliminary study. J Cosmet Laser Ther 15:5 (2013): 255-259.
Jacob C. Treatment of hyperhidrosis with microwave technology. Seminars in Cutaneous Medicine and Surgery 32 (2013): 2-8.
Rokhsar C, Kim MJ. A retrospective analysis of the treatment of axillary hyperhidrosis with a novel microwave technology, presented at the 33rd ASLMS Annual Conference, April 3-7, 2013, Boston, MA.
Biehle-Hulette S et al. Significant protection from event sweat – without a prescription, presented at the American Academy of Dermatology 71st Annual Meeting, March 1-5, 2013, Miami Beach, FL .
Scarff JR. Options for treating antidepressant-induced sweating. Current Psychiatry 12:1 (2013): 51.
Letada, PR, et al. Treatment of focal axillary hyperhidrosis using a long-pulsed Nd:YAG 1064 nm laser at hair reduction settings. J Drugs Dermatol 11:1 (2012): 59-63.
Gagnon L. Laser therapy provides permanent solution to hyperhidrosis. Dermatology Times, 1 July 2012.
Bechara FG, et al. Effects of a long-pulsed 800-nm diode laser on axillary hyperhidrosis: a randomized controlled half-side comparison study. Dermatol Surg 38:5 (2012): 736-740.
Glaser DA et al. A randomized, blinded clinical evaluation of a novel microwave device for treating axillary hyperhidrosis: the dermatologic reduction in underarm perspiration study. Dermatol Surg 38 (2012): 185-191.
JohnsonJ et al. Microwave thermolysis of sweat glands. Lasers in Surgery and Medicine 44:1 (2012): 20-25.
Wolosker N et al. "A randomized placebo-controlled trial of oxybutynin for the initial treatment of palmar and axillary hyperhidrosis". Journal of Vascular Surgery 55:6 (2012): 1696-1700.
Paller AS et al. Oral glycopyrrolate as second-line treatment for primary pediatric hyperhidrosis. J Am Acad Dermatol 67:5 (2012): 918-923.
Rubin D et al. “Second-hand stress: inhalation of stress sweat enhances neural response to neutral faces”. Soc Cogn Affect Neurosci 7:2 (2012): 208-212.
Kerscher M et al. "Comparison of the spread of three botulinum toxin type A preparations". Arch Dermatol Res 304 (2012): 155-161.
Kayser SC et al. Perioral gustatory sweating: case report. The Journal of Laryngology & Otology 126 (2012): 532-534.
Hong H et al. Clinical evaluation of a microwave device for treating axillary hyperhidrosis. Dermatol Surg doi: 10.1111/j.1524-4725.2012.02375.x.
Walling H. Systemic therapy for primary hyperhidrosis: a retrospective study of 59 patients treated with glycopyrrolate or clonidine. J Am Acad Dermatol 66:3 (2012): 387-392.
Wolosker N et al. Evaluation of quality of life over time among 453 patients with hyperhidrosis submitted to endoscopic thoracic sympathectomy. Journal of Vascular Surgery 55:1 (2012): 154-156.
Salvaggio HL, Wagner A. Suture boots: an aid for the injection of onabotulinum toxin A for primary focal hyperhidrosis. Pediatric Dermatology doi: 10.1111/j.1525-1470.2012.01849.x.
Swaile DF et al. Clinical studies of sweat rate reduction by an over-the-counter soft-solid antiperspirant and comparison with a prescription antiperspirant product in male panelists. Br J Dermatol 166 Suppl. 1 (2012): 22-26.
Saenz JW, Sams RW, Jamieson B. Treatment of Hyperhidrosis. Am Fam Physician. 2011 Feb 15;83(4):464-466.
Maletic D et al. Laser assisted reduction of axillary hyperhidrosis (LARAH) – evaluation of success up to 24 months after the treatment. J. LAHA 2011:1 (2011): 37-42.
Kotlus BS. Treatment of refractory axillary hyperhidrosis with a 1320-nm Nd:YAG laser. J Cosmet Laser Ther 13:4 (2011): 193-195.
Smith SR. Evolution of a new treatment modality for primary focal hyperhidrosis, presented at Cosmetic Boot Camp 2011, June 14-17, 2011, Aspen, CO.
Martin A et al. Effective prevention of stress-induced sweating and axillary malodour formation in teenagers. Int J Cosmet Sci 33:1 (2011): 90-97.
Wang F et al. Comparison of compensatory sweating and quality of life following thoracic sympathetic block for palmar hyperhidrosis: electrocautery hook versus titanium clip. Chinese Medical Journal 124:21 (2011): 3495-3498.
Atkinson J et al. Endoscopic transthoracic limited sympathotomy for palmar-plantar hyperhidrosis: outcomes and complications during a 10-year period. Mayo Clin Proc 86:8 (2011): 721-729.
Walling HW, Swick, BL. Treatment options for hyperhidrosis. Am J Clin Dermatol 12:5 (2011): 285-295.
Wolosker N et al. The use of oxybutynin for treating axillary hyperhidrosis. Annals of Vascular Surgery 25:8 (2011): 1057-1062.
Woolery-Lloyd H, Valins W. Aluminum chloride hexahydrate in a salicylic acid gel base: a case series of combination therapy with botulinum toxin type A for moderate to severe hyperhidrosis. Cutis 88:1 (2011): 43-45.
Milanez de Campos JR et al. Is age group a predictive factor for satisfaction among patients undergoing sympathectomy to treat hyperhidrosis? J Vasc Bras 10:4 (2011): 284-288.
Wolosker N et al. The use of oxybutynin for treating facial hyperhidrosis. An Bras Dermatol 86:3 (2011): 451-456.
Doft MA, et al. Treatment of axillary hyperhidrosis with botulinum toxin: a single surgeon's experience with 53 consecutive patients. Aesthetic Plast Surg 2011 May 11.
Lupin M et al. A multi-center evaluation of the miradry system to treat subjects with axillary hyperhidrosis, presented at the 31st ASLMS Annual Conference, April 1-3, 2011, Grapevine, TX.
Kilmer S et al. A randomized, blinded clinical study of a microwave device for treatment of axillary hyperhidrosis, presented at the 31st ASLMS Annual Conference, April 1-3, 2011, Grapevine, TX.
Wait SD. et al. Thoracoscopic sympathectomy for hyperhidrosis: analysis of 642 procedures with special attention to horner’s syndrome and compensatory hyperhidrosis. Neurosurgery 67:3 (2010): 652-657.
Kaminer MS et al. First clinical use of a novel microwave device for treatment of axillary hyperhidrosis, presented at the American Society for Dermatologic Surgery 2010 Annual Meeting, October 21-24, 2010, Chicago, IL.
Marques AH et al. Evaluation of stress symptoms by applying noninvasive methodologies: measurements of neuroimmune biomarkers in the sweat, heart rate variability and salivary cortisol. Neuroimmunomodulation 17:3 (2010): 205-208.
Dressler D. Comparing Botox® and Xeomin® for axillar hyperhidrosis. J Neural Transm 117 (2010): 317-319.
Cantarella G et al. Treatment of Frey’s syndrome with botulinum toxin B. Otolaryngol Head Neck Surg 143 (2010): 214-218.
Glaser DA et al. A randomized, blinded clinical evaluation of a novel microwave device for treatment of axillary hyperhidrosis, presented at the 2010 ASDS/ASCDAS Joint Annual Meeting, October 21-24, 2010, Chicago, IL.
Hill S. Hyperhidrosis Diagnosis and Management. Pediatric Rounds, a newsletter from the physicians of Children's Specialty Group, (Fall 2010) 12-14.
Shams K, Kavanagh GM. Immediate reduction in sweat secretion with electric current application in primary palmar hyperhidrosis. Archdermatol doi: 10.1001/archdermatol.2010.300.
Bellet JS. Diagnosis and treatment of primary focal hyperhidrosis in children and adolescents. Semin Cutan Med Surg 29:2 (2010): 121-126.
Prasad A et al. Endoscopic thoracic sympathectomy for primary palmar hyperhidrosis. Surg Endosc 24 (2010): 1952-1957.
Milanez de Campos JR et al. Comparison of pain severity following video-assisted thoracoscopic sympathectomy: electric versus harmonic scalpels. Interactive Cardiovascular and Thoracic Surgery 10 (2010): 919-922.
Wolosker Nelson, et al. Is gender a predictive factor for satisfaction among patients undergoing sympathectomy to treat palmar hyperhidrosis? Clinics 65:6 (2010): 583-586.
Wolosker N et al. Quality of life before surgery is a predictive factor for satisfaction among patients undergoing sympathectomy to treat hyperhidrosis. Journal of Vascular Surgery 51:5 (2010): 1190-1194.
Kenny K. Diagnosis and treatment of hyperhidrosis. Nurse Practitioner: July 2009, Volume 34, Issue 7, p 10–11.
Carriere, I et al. Drugs with anticholinergic properties, cognitive decline, and dementia in an elderly general population. Arch Intern Med 169:14 (2009): 1317-1324.
Commons, GW, Lim AF. Treatment of axillary hyperhidrosis/bromidrosis using Vaser ultrasound. Aesthetic Plast Surg 33:3 (2009): 312-323.
Kim WO et al. Botulinum toxin: a treatment for compensatory hyperhidrosis in the trunk. Dermatol Surg 35:5 (2009): 833-838.
Mujica-Parodi LR et al. Chemosensory cues to conspecific emotional stress activate amygdale in humans. PLoS One doi: 10.1371/journal.pone.0006415.
Prehn-Kristensen A et al. Induction of empathy by the smell of anxiety. PLoS One doi: 10.1371/journal.pone.0005987.
Scully C et al. Marathon of eponyms: 6 Frey syndrome (gustatory sweating). Oral Diseases 15 (2009): 608-609.
de Bree R et al. Repeated botulinum toxin type A injections to treat patients with Frey syndrome. Arch Otolaryngol Head Neck Surg 135:3 (2009): 287-290.
Ng S et al. Management of Frey syndrome using botulinum neurotoxin: a case report. JCDA 75:9 (2009): 651-654.
Baron JA, Zloty DM. Bilateral type 1 complex regional pain syndrome after local nerve blocks for palmar hyperhidrosis. Dermatol Surg 35 (2009): 885-887.
Mahendiran S et al. Hyperhidrosis: a review of a medical condition. The Open Dermatology Journal 3 (2009): 195-197.
Flanagan KH, Glaser DA. An open-label trial of the efficacy of 15% aluminum chloride in 2% salicylic acid gel base in the treatment of moderate-to-severe primary axillary hyperhidrosis. Journal of Drugs in Dermatology 8:5 (2009): 477-480.
Jones T et al. Safety and tolerability of topical botulinum toxin type A in healthy adults, presented at the 69th Annual Meeting of the Society for Investigative Dermatology, May 2009, Montreal, Canada.
American Academy of Dermatology Responds to FDA Decision Regarding Botulinum Toxin Products, Schaumburg, IL, April 2009.
Walling HW. Primary hyperhidrosis increases the risk of cutaneous infection: a case-control study of 387 patients. J Am Acad Dermatol doi: 10.1016/j.jaad.2009.02.038.
Keller SM et al. Diagnosis of palmar hyperhidrosis via questionnaire without physical examination. Clin Auton Res doi: 10.1007/s10286-009-0006-5.
Goldman A, Wollina U. Subdermal Nd-YAG laser for axillary hyperhidrosis. Dermatol Surg 35:6 (June 2009):1018
Grunfeld A et al. Botulinum toxin for hyperhidrosis. Am J Clin Dermatol 10:2 (2009): 87-102.
Miller DL et al. Effect of sympathectomy level on the incidence of compensatory hyperhidrosis after sympathectomy for palmar hyperhidrosis. J Thorac Cardiovasc Surg 138 (2009): 581-585.
Cruz J et al. Effects of endoscopic thoracic sympathectomy for primary hyperhidrosis on cardiac autonomic nervous activity. The Journal of Thoracic and Cardiovascular Surgery 137:3 (2009): 664-669.
Chow A, Wilder-Smith EP. Effect of transdermal botulinum toxin on sweat secretion in subjects with idiopathic palmar hyperhidrosis. Br J Dermatol 160:3 (2009): 721-722.
Cetindag IB, Boley TM, Webb KN, Hazelrigg SR. Long-term results and quality-of-life measures in the management of hyperhidrosis. ThoracSurg Clin 18:2 (2008): 217-222.
Kim WO et al. Topical glycopyrrolate for patients with facial hyperhidrosis. Br J Dermatol 158 (2008): 1094-1097.
Laing TA et al. Botulinum toxin for treatment of glandular hypersecretory disorders. Journal of Plastic, Reconstructive & Aesthetic Surgery 61 (2008): 1024-1028.
Bahmer FA, Sachse MM. Hyperhidrosis area and severity index. Dermatol Surg 34 (2008): 1744-1745.
Gelbard CM et al. Primary pediatric hyperhidrosis: a review of current treatment options. Pediatric Dermatology 25:6 (2008): 591-598.
Kossintseva I, Barankin B. Improvement in both raynaud disease and hyperhidrosis in response to botulinum toxin type A treatment. Journal of Cutaneous Medicine and Surgery 12:4 (2008): 189-193.
Efthymiou CA, Thorpe JAC. Compensatory hyperhidrosis: a consequence of truncal sympathectomy treated by video assisted application of botulinum toxin and reoperation. European Journal of Cardio-thoracic Surgery 33 (2008): 1157-1158.
Hartl DM, et al. Botulinum toxin A for quality of life improvement in post-parotidectomy gustatory sweating (Frey’s syndrome). The Journal of Laryngology & Otology 122 (2008): 1100-1104.
Honeyman JF et al. Efficacy of botulinum toxin for a congenital eccrine naevus. J Eur Acad Dermatol Venereol 22:10 (2008): 1275-1276.
Munia MAS et al. Sustained benefit lasting one year from T4 instead of T3-T4 sympathectomy for isolated axillary hyperhidrosis. Clinics 63:6 (2008): 771-774.
Flanagan KH et al. Botulinum toxin type A versus topical 20% aluminum chloride for the treatment of moderate to severe primary focal axillary hyperhidrosis. Journal of Drugs in Dermatology 7:3 (2008): 221-227.
Smalls LK et al. Clinical comparison of otc products labeled prescription strength wetness protection to prescription antiperspirants, presented at the 66th Annual Meeting of the American Academy of Dermatology, February 1-5, 2008, San Antonio, TX.
Smalls LK et. al. Chromophore mapping of hemoglobin for the assessment of axillary irritation: comparison of otc and prescription antiperspirants, presented at the 66th Annual Meeting of the American Academy of Dermatology, February 1-5, 2008, San Antonio, TX.
Cheshire WP, Fealey RD. Drug-induced hyperhidrosis and hypohidrosis. Drug Safety 31:2 (2008): 109-126.
Pomprasit M, Chintrakam C. Treatment of Frey’s syndrome with botulinum toxin. J Med Assoc Thai 90:11 (2007): 2397-2402.
de Bree R et al. Management of Frey syndrome. Head & Neck 29:8 (2007): 773-778.
Na GY et al. Control of palmar hyperhidrosis with a new 'dry-type' iontophoretic device. Dermatol Surg 33 (2007): 57-61.
Solish N et al. A comprehensive approach to the recognition, diagnosis, and severity-based treatment of focal hyperhidrosis: recommendations of the canadian hyperhidrosis advisory committee. Dermatol Surg 33 (2007): 908-923.
Bechara FG et al. Focal hyperhidrosis of the anal fold: successful treatment with botulinum toxin A. Dermatol Surg 33 (2007): 924-927.
NAD Examines Advertising for P&G's Secret Clinical Strength, NAD News, National Advertising Review Council, New York, NY, July 2007.
Glaser DA et al. Primary focal hyperhidrosis: scope of the problem. Cutis 79:suppl 5 (2007): 5-17.
Glaser DA et al. Palmar and plantar hyperhidrosis: best practice recommendations and special considerations. Cutis 79:suppl 5 (2007): 18-28.
Glaser DA et al. Facial hyperhidrosis: best practice recommendations and special considerations. Cutis 79:suppl 5 (2007): 29-32.
Ram R et al. Current and emerging therapeutic modalities for hyperhidrosis, part 2: moderately invasive and invasive procedures. Cosmetic Dermatology 79 (2007): 281-288.
Glaser DA et al. Functional and dermatology-specific quality of life benefits with repeated botulinum toxin type A treatment of primary axillary hyperhidrosis over 4 years, presented at the 65th Annual Meeting of the American Academy of Dermatology, February 2-6, 2007, Washington, DC.
Kessler E et al. A demographical study of hyperhidrosis, presented at the 65th Annual Meeting of the American Academy of Dermatology, February 2-6, 2007, Washington, DC.
Glaser DA et al. 4-Year longitudinal data on the efficacy and safety of repeated botulinum toxin type A therapy for primary axillary hyperhidrosis, presented at the 65th Annual Meeting of the American Academy of Dermatology, February 2-6, 2007, Washington, DC.
Thomas M et al. Alternative topical treatment to an aluminum chloride antiperspirant that provides prescription strength efficacy with significantly less irritation, presented at the 65th Annual Meeting of the American Academy of Dermatology, February 2-6, 2007, Washington, DC.
Munia MAS et al. A randomized trial of T3-T4 versus T4 sympathectomy for isolated axillary hyperhidrosis. Journal of Vascular Surgery 45:1 (2007): 130-133.
Aghaei S. Botulinum toxin therapy for palmar hyperhidrosis: experience in an Iranian population. The International Society of Dermatology 46 (2007): 212-214.
Lear W et al. An epidemiological study of hyperhidrosis. Dermatol Surg 33 (2007): S69-S75.
Talarico-Filho S et al. A double-blind, randomized, comparative study of two type A botulinum toxins in the treatment of primary axillary hyperhidrosis. Dermatol Surg 33 (2007): S44-S50.
Glogau RG. Topically applied botulinum toxin type A for the treatment of primary axillary hyperhidrosis: results of a randomized, blinded, vehicle-controlled study. Dermatol Surg 33 (2007): S76-S80.
Izadi S et al. Mydriasis and accommodative failure from exposure to topical glycopyrrolate used in hyperhidrosis. J Neuroophthalmol 26 (2006): 232-233.
Glaser DA. The use of botulinum toxins to treat hyperhidrosis and gustatory sweating syndrome. Neurotoxicity Research 9:2-3 (2006): 173-178.
Dressler D, Eleopra R. Clinical use of non-A botulinum toxins: botulinum toxin type B. Neurotoxicity Research 9:2-3 (2006): 121-125.
Khoo SG et al. The use of botulinum toxin in Frey’s syndrome. IMJ 99:5 (2006): 136-137.
Bakke M et al. Treatment of gustatory sweating with low-dose botulinum toxin A. Acta Odontologica Scandinavica 64:3 (2006): 129-133.
Lim ECH et al. Topical botulinum toxin to treat hyperhidrosis? No sweat! Medical Hypotheses 67 (2006): 27-32.
Milanez de Campos JR et al. Axillary hyperhidrosis: T3/T4 versus T4 thoracic sympathectomy in a series of 276 cases. Journal of Laparoendoscopic & Advanced Surgical Techniques 16:6 (2006): 598-603.
Barankin B et al. Treatment of inguinal hyperhidrosis with botulinum toxin type A. International Journal of Dermatology 45 (2006): 985-986.
Kavanagh GM, Shams K. Botulinum toxin type A by iontophoresis for primary palmar hyperhidrosis. Journal of the American Academy of Dermatology 55:5 (2006): S115-S117.
Kavanagh GM et al. Topical glycopyrrolate should not be overlooked in treatment of focal hyperhidrosis. British Journal of Dermatology 155:2 (2006): 487.
Pariser D et al. Effect of botulinum toxin type A treatment for severe primary axillary hyperhidrosis on work performance and productivity: results from an open-label clinical study, presented at the 64th Annual Meeting of the American Academy of Dermatology, March 3-7, 2006, San Francisco, CA.
Thomas M et al. Panel discussions among hyperhidrosis patients to assess lifestyle limitations, treatment regimes, and compensating behaviors, presented at the 64th Annual Meeting of the American Academy of Dermatology, March 3-7, 2006, San Francisco, CA.
Hamm H et al. Primary focal hyperhidrosis: disease characteristics and functional impairment. Dermatology 2006 212 (2006): 343-353.
Moya J et al. Thoracic sympathicolysis for primary hyperhidrosis. Surg Endosc 20 (2006): 598-602.
Cliff SH, Reeken S. Axillary hyperhidrosis and botox responding to demands: starting a nurse-led service. Nurse2Nurse 5:1 (2005): 28-30.
Eisenach JH et al. Hyperhidrosis: evolving therapies for a well-established phenomenon. Mayo Clinic Proceedings 80:5 (2005): 657-666.
Glaser DA et al. Effect of repeated botulinum toxin type A treatment on health related quality of life and functioning in patients with primary axillary hyperhidrosis: results from 2 years of longitudinal data, presented at ACADEMY '05 American Academy of Dermatology Summer Meeting, July 20-24, 2005, Chicago, IL.
Glaser DA et al. Efficacy and safety of repeated botulinum toxin type A treatment for primary axillary hyperhidrosis: 12-month interim analysis of a multicenter, open-label trial, presented at ACADEMY ’05 American Academy of Dermatology Summer Meeting, July 20-24, 2005, Chicago, IL.
Haider A, Solish N.Focal hyperhidrosis: diagnosis and management. CMAJ 172:1 (2005): 1-7.
Kowalski JW et al. Cost-effectiveness and budget impact of botulinum toxin type A (BoNTA) treatment for severe primary axillary hyperhidrosis inadequately managed with topical agents, presented at ACADEMY ’05 American Academy of Dermatology Summer Meeting, July 20-24, 2005, Chicago, IL.
Krogstad AL et al. No compensatory sweating after botulinum toxin treatment of palmar hyperhidrosis. Br J Dermatol 152:2 (Feb 2005): 329-333.
Ogata A, et al. Low and high frequency acupuncture stimulation inhibits mental stress-induced sweating in humans via different mechanisms. Auton Neurosci 118: 1-2 (2005): 93-101.
Neumayer C et al. Effect of endoscopic thoracic sympathetic block on plantar hyperhidrosis. Arch Surg 140: 676-680 (2005).
Solish N et al. Prospective open-label study of botulinum toxin type A in patients with axillary hyperhidrosis: effects on functional impairment and quality of life. Dermatol Surg 31:4 (2005): 405-413.
Swaile D, Chabi G, Putnam C. Clinical comparison of antiperspirant efficacy as a function of morning and/or nighttime application, presented at ACADEMY '05 American Academy of Dermatology Summer Meeting, July 20-24, 2005, Chicago, IL.
Weber A et al. Psychosocial aspects of patients with focal hyperhidrosis. Marked reduction of social phobia, anxiety and depression and increased quality of life after treatment with botulinum toxin A. British Journal of Dermatology, (2005) 152: 342–345.
Thomas S, Brown J, Vafaie J, Schwartz R. Palmoplantar Hyperhidrosis: A Therapeutic Challenge. Am Fam Physician. 2004 Mar 1;69(5):1117-1121.
Dickerson SS, Kemeny ME. Acute stressors and cortisol responses: a theoretical integration and synthesis of laboratory research. Psychol Bull 130:3 (2004): 355-391.
Lowe N et al. The place of botulinum toxin type A in the treatment of focal hyperhidrosis. Br J Dermatol 151:6 (Dec 2004): 1115-1122.
Lee J et al. A case of foul genital odor treated with botulinum toxin A. Dermatologic Surgery doi: 10.1111/j.1524-4725.2004.30382.x.
Campanati A et al. Local neural block at the wrist for treatment of palmar hyperhidrosis with botulinum toxin: technical improvements. Journal of the American Academy of Dermatology 51:3 (2004): 345-348.
Strutton D et al. US prevalence of hyperhidrosis and impact on individuals with axillary hyperhidrosis: results from a national survey. Journal of the American Academy of Dermatology 51:2 (2004): 241-248.
Hornberger J et al. Recognition, diagnosis, and treatment of primary focal hyperhidrosis. Journal of the American Academy of Dermatology 51:2 (2004): 274-286.
Glaser DA et al. Botulinum toxin type A improves occupational impairment associated with primary axillary hyperhidrosis and results in high levels of satisfaction with treatment, presented at the American Academy of Dermatology Summer Meeting, July 28- August 1, 2004, New York, NY.
Carruthers A, Carruthers J. Long-term safety review of subjects treated with botulinum toxin type A for cosmetic use, presented at the American Academy of Dermatology Summer Meeting, July 28- August 1, 2004, New York, NY.
Dolianitis C et al. Iontophoresis with glycopyrrolate for the treatment of palmoplantar hyperhidrosis. Australasian Journal of Dermatology 45 (2004): 208-212.
Kavanagh GM et al. Botox® delivery by iontophoresis. British Journal of Dermatology 151 (2004): 1093-1095.
Kowalski JW, Eadie N, Dagget S, Lai PY. Validity and reliability of the hyperhidrosis disease severity scale (HDSS). J Am Acad Dermatol 50:3 (2004): P51.
Ojimba TA, Cameron AEP. Drawbacks of endoscopic thoracic sympathectomy. British Journal of Surgery 91 (2004): 264-269.
Hund M et al. Randomised, placebo-controlled, double blind clinical trial for the evaluation of the efficacy and safety of oral methanthelinium bromide (Vagantin®) in the treatment of focal hyperhidrosis. JDDG;2004· 2:343-349. (English, without graphs)
Hund M et al. Randomised, placebo-controlled, double blind clinical trial for the evaluation of the efficacy and safety of oral methanthelinium bromide (Vagantin®) in the treatment of focal hyperhidrosis. JDDG;2004· 2:343-349. (German, with graphs)
Hexsel DM et al. Inguinal, or hexsel’s hyperhidrosis. Clinics in Dermatology 22 (2004): 53-59.
Atkinson JLD, Fealey RD. Sympathotomy instead of sympathectomy for palmar hyperhidrosis: minimizing postoperative compensatory hyperhidrosis. Mayo Clinic Proceedings 78:2 (2003): 167-172.
Baumann L. Systemic adverse effects after botulinum toxin type B (myobloc) injections for the treatment of palmar hyperhidrosis. Arch Dermatol 139 (2003): 226-227.
Belin E, Polo J. Treatment of compensatory hyperhidrosis with botulinum toxin type A. Cutis 71 (2003): 68-70.
Blaheta H, Deusch H, Rassner G, Vollert B. Intravenous regional anesthesia (Bier's block) is superior to a peripheral nerve block for painless treatment of plantar hyperhidrosis with botulinum toxin. J Am Acad Dermatol 48:2 (2003): 302-304.
Connolly M, de Berker D. Management of primary hyperhidrosis. Am J Clin Dermatol 4:10 (2003): 681-697.
Goodman, G. Diffusion and short-term efficacy of botulinum toxin A after the addition of hyaluronidase and its possible application for the treatment of axillary hyperhidrosis. Dermatol Surg 29:5 (2003): 533-538.
Gossot D et al. Long-term results of endoscopic thoracic sympathectomy for upper limb hyperhidrosis. Ann Thoracic Surg 75 (2003): 1075-1079.
Lowe P, Cerdan-Sanz S, Lowe N. Botulinum toxin type A in the treatment of bilateral primary axillary hyperhidrosis: efficacy and duration with repeated treatments. Dermatol Surg 29 (2003): 545-548.
Matthews B et al. Thoracoscopic sympathectomy for palmaris hyperhidrosis. Southern Medical Journal 96:3 (2003): 254-258.
Naumann, M et al. Comparing the quality of life effect of primary focal hyperhidrosis to other dermatological conditions as assessed by the dermatology life quality index (DLQI). Value In Health, The Journal of The International Society for Pharmacoeconomics and Outcomes Research 6:3 (2003): 242.
Naumann M et al. Botulinum toxin type A is a safe and effective treatment for axillary hyperhidrosis over 16 months. Arch Dermatol 139 (2003): 731-736.
Kaufmann H et al. Primary hyperhidrosis. Clin Auton Res 13 (2003): 96-98.
Anliker M, Kreyden O. Tap water iontophoresis. Curr Probl Dermatol 30 (2002): 48-56.
Atkins JL, Butler PE. Hyperhidrosis: a review of current management. Plast Reconstr Surg 110 (2002): 222-228.
Ackerl K et al. The scent of fear. Neuro Endocrinol Lett 23:2 (2002): 79-84.
Altman R, Schwartz R. Emotionally induced hyperhidrosis. Cutis 69:5 (2002): 336-338.
Aoki K. Physiology and pharmacology of therapeutic botulinum neurotoxins. Curr Probl Dermatol 30 (2002): 107-116.
Beerens A, Snow G. Botulinum toxin A in the treatment of patients with Frey syndrome. British Journal of Surgery 89 (2002): 116-119.
Boni R. Generalized hyperhidrosis and its systemic treatment. Curr Probl Dermatol 30 (2002): 44-47.
Chuang K, Liu J. Long-term assessment of percutaneous sterotactic thermocoagulation of upper thoracic ganglionectomy and sympathectomy for palmar and craniofacial hyperhidrosis in 1742 cases. Neurosurgery 51:4 (2002): 963-969.
Davidson JRT et al. Hyperhidrosis in social anxiety disorder. Progress in Neuro-Psychopharmacology & Biological Psychiatry 26 (2002): 1327-1331.
Geiges M. The history of botulism. Curr Probl Dermatol 30 (2002): 77-93.
Groscurth P. Anatomy of sweat glands. Curr Probl Dermatol 30 (2002): 1-9.
Hafner J, Beer G. Axillary sweat gland excision. Curr Probl Dermatol 30 (2002): 57-63.
Heckmann M. Hyperhidrosis of the axilla. Curr Probl Dermatol 30 (2002): 149-155.
Holzle E. Pathophysiology of sweating. Curr Probl Dermatol 30 (2002): 10-22.
Holzle E. Topical pharmacological treatment. Curr Probl Dermatol 30 (2002): 30-43.
Huh C, Han K, Seo K, Eun H. Botulinum toxin treatment for a compensatory hyperhidrosis subsequent to an upper thoracic sympathectomy. Journal of Dermatological Treatment 13 (2002): 91-93.
Hund M, Kinkelin I, Naumann M, Hamm H. Definition of axillary hyperhidrosis by gravimetric assessment. Arch Dermatol 138 (2002): 539-541.
Karakoç Y, et al. Safe control of palmoplantar hyperhidrosis with direct electrical current. Int J Dermatol 41 (2002): 602-605.
Kestenholz P, Weder W. Thoracic sympathectomy. Curr Probl Dermatol 30 (2002): 64-76.
Kreyden O. Botulinum toxin: from poison to pharmaceutical. Curr Probl Dermatol 30 (2002): 94-100.
Kreyden O. Rare forms of hyperhidrosis. Curr Probl Dermatol 30 (2002): 178-187.
Laskawi R, Rohrbach S. Frey's syndrome. Treatment with botulinum toxin. Curr Probl Dermatol 30 (2002): 170-177.
Lin T, Chou M. Needlescopic thoracic sympathetic block by clipping for craniofacial hyperhidrosis. Surg Endosc 16 (2002): 1055-1058.
Lowe N et al. Efficacy and safety of botulinum toxin type A in the treatment of palmar hyperhidrosis: a double-blind, randomized, placebo-controlled study. Dermatol Surg 28 (2002): 822-827.
Luh J, Blackwell T. Craniofacial hyperhidrosis successfully treated with topical glycopyrrolate. South Med J 95:7 (2002): 756-758.
Moraru E, Auff E, Schnider P. Hyperhidrosis of the palms and soles. Curr Probl Dermatol 30 (2002): 156-169.
Naumann M, Hamm H. Treatment of axillary hyperhidrosis. British Journal of Surgery 89 (2002): 259-261.
Odderson I. Long-term quantitative benefits of botulinum toxin type A in the treatment of axillary hyperhidrosis. Dermatol Surg 28 (2002): 480-483.
Proebstle T, Schneiders V, Knop J. Gravimetrically controlled efficacy of subcorial curettage: a prospective study for treatment of axillary hyperhidrosis. Dermatol Surg 28 (2002): 1022-1026.
Restivo D et al. Improvement of diabetic autonomic gustatory sweating by botulinum toxin type A. Neurology 59 (2002): 1971-1973.
Ro KM, Cantor RM, Lange KL, Ahn SS. Palmar hyperhidrosis: evidence of genetic transmission. J Vasc Surg 35:2 (2002): 382-386.
Rossetto O, Seveso M, Caccin P, Montecucco C. Botulinum neurotoxins are metalloproteases specific for SNARE proteins involved in neuroexocytosis. Curr Probl Dermatol 30 (2002): 117-125.
Ruchinskas R, Narayan R, Meagher R, Furukawa S. Psychodermatology: the relationship of psychopathology and hyperhidrosis. British Journal of Dermatology 147 (2002): 733-735.
Schaffner R, Kreyden O. Complications and side-effects of botulinum toxin A. Curr Probl Dermatol 30 (2002): 141-148.
Tögel B et al. Current therapeutic strategies for hyperhidrosis: a review. Eur J Dermatol 12 (2002): 219-223.
Tan SR, Solish N. Long-term efficacy and quality of life in the treatment of focal hyperhidrosis with botulinum toxin A. Dermatol Surg 28:6 (2002): 495-499.
Naumann MK et al. Effect of botulinum toxin type A on quality of life measures in patients with excessive axillary sweating: a randomized controlled trial. Brit J Dermatol 147 (2002): 1218-1226.
Wollina U, Karamfilov T, Konrad H. High-dose botulinum toxin type A therapy for axillary hyperhidrosis markedly prolongs the relapse-free interval. J Am Acad Dermatol 46:4 (2002): 536-540.
Chen H, Lu K, Liang C. Transthoracic endoscopic T-2, 3 sympathectomy for facial hyperhidrosis. Autonomic Neuroscience: Basic and Clinical 93 (2001): 91-94.
Hsu C, Shia S, Hsia J, Chuang C, Chen, C. Experiences in thoracoscopic sympathectomy for axillary hyperhidrosis and osmidrosis. Arch Surg 136 (2001): 1115-1117.
Kreyden O, Schmid-Grendelmeier P, Burg G. Idiopathic localized unilateral hyperhidrosis. Arch Dermatol 137 (2001): 1622-1625.
Trindade de Almeida A, Kadunc B, Martins de Oliveira E. Improving botulinum toxin therapy for palmar hyperhidrosis: wrist block and technical considerations. Dermatol Surg 27:1 (2001): 34-36.
Fujita M, Mann T, Mann O, Berg D. Surgical pearl: use of nerve blocks for botulinum toxin treatment of palmar-plantar hyperhidrosis. J Am Acad Dermatol 45 (2001): 587-589.
Glogau, R. Treatment of palmar hyperhidrosis with botulinum toxin. Seminars in Cutaneous Medicine and Surgery 20:2 (2001): 101-108.
Heckmann M, Ceballos-Baumann A, Plewig G. Botulinum toxin A for axillary hyperhidrosis (excessive sweating). N Engl J Med 344:7 (2001): 488-493.
Heckmann M, Schaller M, Breit S, Plewig G. Evaluation of therapeutic success of hyperhidrosis therapy. Arch Dermatol 137 (2001): 94.
Naumann M. Evidence-based medicine: botulinum toxin in focal hyperhidrosis. J Neurol 248 :S:Suppli (2001): 31-33. :S:Suppli (2001): 31-33.
Naumann M, Lowe NJ. Botulinum toxin type A in treatment of bilateral primary axillary hyperhidrosis: randomized, parallel group, double blind, placebo controlled trial. BMJ 323 (2001): 596-599.
Rompel R, Scholz S. Subcutaneous curettage vs. injection of botulinum toxin A for treatment of axillary hyperhidrosis. JEADV 15 (2001): 207-211.
Saadia D, Voustianiouk A, Wang A, Kaufmann H. Botulinum toxin type A in primary palmar hyperhidrosis. Neurology 57 (2001): 2095-2099.
Schnider P et al. Treatment of focal hyperhidrosis with botulinum toxin type A: long-term follow-up in 61 patients. British Journal of Dermatology 145 (2001): 289-293.
Swartling C, Naver H, Lindberg M. Botulinum A toxin improves life quality in severe primary focal hyperhidrosis. European Journal of Neurology 8 (2001): 247-252.
Swartling C, Farnstrand C, Abt G, Stalberg E, Naver H. Side effects of intradermal injections of botulinum A toxin in the treatment of palmar hyperhidrosis: a neurophysiological study. European Journal of Neurology 8 (2001): 451-456.
Amir M et al. Impairment in quality of life among patients seeking surgery for hyperhidrosis (excessive sweating): preliminary results. Isr J Psychiatry Relat Sci 37:1 (2000): 25-31.
Birner P et al. Cardiac autonomic function in patients suffering from primary focal hyperhidrosis. Eur Neurol 44 (2000): 112-116.
Collin J, Whatling P. Treating hyperhidrosis: surgery and botulinum toxin are treatments of choice in severe cases. BMJ 320 (2000): 1221-1222.
Huang W, Foster J, Rogachefsky A. Pharmacology of botulinum toxin. J Am Acad Dermatol 43 (2000): 249-259.
Karamfilov T, Konrad H, Karte K, Wollina U. Lower relapse rate of botulinum toxin A therapy for axillary hyperhidrosis by dose increase. Arch Dermatol 136 (2000): 487-490.
Kinkelin I et al. Effective treatment of frontal hyperhidrosis with botulinum toxin A. British Journal of Dermatology143:4 (2000): 824-827.
Klein A, Glogau R. Botulinum toxin: beyond cosmesis. Arch Dermatol 136 (2000): 539-541.
Manca D, Valls-Sole J, Callejas M. Excitability recovery curve of the sympathetic skin response in healthy volunteers and patients with palmar hyperhidrosis. Clinical Neurophysiology 111 (2000): 1767-1770.
Solomon B, Hayman R. Botulinum toxin type A therapy for palmar and digital hyperhidrosis. J Am Acad Dermatol 42:6 (2000): 1026-1029.
Schnider P et al. High-dose botulinum toxin type A for axillary hyperhidrosis. Arch Dermatol 136 (2000): 1567.
Sung S, Kim Y, Kim J. Ultra-thin needle thoracoscopic surgery for hyperhidrosis with excellent cosmetic effects. European Journal of Cardio-thoracic Surgery 17 (2000): 691-696.
Swinehart JM. Treatment of axillary hyperhidrosis: combination of the starch-iodine test with the tumescent liposuction technique. Dermatol Surg 26 (2000): 392-396.
Yamamoto H, Kanehira A, Kawamura M, Okada M, Ohkita Y. Needlescopic surgery for palmar hyperhidrosis. The Journal of Thoracic and Cardiovascular Surgery 120:2 (2000): 276-279.
Cina CS, Clase CM. The illness intrusiveness rating scale: a measure of severity in individuals with hyperhidrosis. Qual Life Res 8 (1999):693-698.
Imhof M et al. Long-term results of 45 thoracoscopic sympathicotomies for primary hyperhidrosis in children. Journal of Pediatric Surgery 34:12 (1999): 1839-1842.
Heckmann M et al. Side-controlled intradermal injection of botulinum toxin A in recalcitrant axillary hyperhidrosis. J Am Acad Dermatol 41:6 (1999): 987-990.
Laccourreye O et al. Recurrent gustatory sweating (frey's syndrome) after intracutaneous injection of botulinum toxin type A. Arch Otolaryngol Head Neck Surg 125 (1999): 283-286.
Laskawi R, Ellies M, Rodel R, Schoenebeck C. Gustatory sweating: clinical implications and etiologic aspects. J Oral Maxillofac Surg 57 (1999): 642-648.
Leung AK, Chan PY, Choi MC. Hyperhidrosis. Int J Dermatol 38:8 (1999): 561-567.
Zacherl J et al. Long-term results of 630 thoracoscopic sympathicotomies for primary hyperhidrosis: the Vienna experience. Eur J Surg 164:Suppl 580 (1998): 43-46.
Benohanian A et al. Localized hyperhidrosis treated with aluminum chloride in a salicylic acid gel base. International Journal of Dermatology 37 (1998): 701-703.
Glogau RG. Botulinum A neurotoxin for axillary hyperhidrosis. No sweat Botox. Dermatol Surg 24 (1998): 817-819.
Heckmann M. Complications in patients with palmar hyperhidrosis treated with transthoracic endoscopic sympathectomy. Neurosurgery 42:6 (1998): 1403-1404.
Naumann M et al. Focal hyperhidrosis. Effective treatment with intracutaneous botulinum toxin. Arch Dermatol 134 (1998): 301-304.
Rex L, Drott C, Claes G, Gothberg G, Dalman P. The Boras experience of endoscopic thoracic sympathicotomy for palmar, axillary, facial hyperhidrosis and facial blushing. Eur J Surg 164:Suppl 580 (1998): 23-26.
Stolman LP. MD. Treatment of hyperhidrosis. Dermatologic Clinics 16:4 (October 1998): 863-867.
Telaranta T. Treatment of social phobia by endoscopic thoracic sympathicotomy. Eur J Surg 164:Suppl 580 (1998): 27-32.
Zacherl J et al. Long-term results of 630 thoracoscopic sympathicotomies for primary hyperhidrosis: the Vienna experience. Eur J Surg 164:Suppl 580 (1998): 43-46.
Andrews B, Rennie J. Predicting changes in the distribution of sweating following thoracoscopic sympathectomy. British Journal of Surgery 84 (1997): 1702-1704.
Garber A. Benztropine in the Treatment of Venlafaxine-Induced Sweating. J Clin Psychiatry 58:4 (1997): 176-177.
Iwase S et al. Altered response in cutaneous sympathetic outflow to mental and thermal stimuli in primary palmoplantar hyperhidrosis. Journal of the Autonomic Nervous Systems 64 (1997): 65-73.
Lai Y, Yang L, Chio C, Chen H. Complications in patients with palmar hyperhidrosis treated with transthoracic endoscopic sympathectomy. Neurosurgery 41:1 (1997): 110-113.
Naumann M et al. Botulinum toxin for palmar hyperhidrosis. The Lancet 349 (1997): 252.
Noppen M, Sevens C, Gerlo E, Vincken W. Plasma catecholamine concentrations in essential hyperhidrosis and effects of thoracoscopic D2-D3 sympathicolysis. European Journal of Clinical Investigation 27 (1997): 202-205.
Park JH et al. Carbon dioxide laser treatment vs subcutaneous resection of axillary osmidrosis. Dermatol Surg 23:4 (1997): 247-251.
Parslew R, Lewis-Jones M. Localized unilateral hyperhidrosis secondary to an eccrine naevus. Clinical and Experimental Dermatology 22 (1997): 246-247
Schnider P et al. Double-blind trial of botulinum A toxin for the treatment of focal hyperhidrosis of the palms. British Journal of Dermatology 136 (1997): 548-552.
Shaw J et al. A randomised controlled trial of topical glycopyrrolate, the first specific treatment for diabetic gustatory sweating. Diabetologia 40 (1997): 299-301.
Kao M, Chen Y, Lin J, Hsieh C, Tsai J. Endoscopic sympathecomy treatment for craniofacial hyperhidrosis. Arch Surg 131 (1996): 1091-1094.
Drott C, Gothberg G, Claes G. Endoscopic transthoracic sympathectomy: an efficient and safe method for the treatment of hyperhidrosis. Journal of the American Academy of Dermatology 33:1 (1995): 78-81.
Feder R. Clonidine treatment of excessive sweating. J Clin Psychiatry 56:1 (1995): 35.
Orteu C, McGregor J, Almeyda J, Rustin M. Recurrence of hyperhidrosis after endoscopic transthoracic sympathectomy—case report and review of the literature. Clinical and Experimental Dermatology 20 (1995): 230-233.
Bushara K, Park D. Botulinum toxin and sweating. Journal of Neurology, Neurosurgery and Psychiatry 57:11 (1994): 1437-1438.
Canaday B, Stanford R. Propantheline bromide in the management of hyperhidrosis associated with spinal cord injury. The Annals of Pharmacotherapy 29 (1995): 489-492.
Herbst F, Plas E, Fugger R, Fritsch A. Endoscopic thoracic sympathectomy for primary hyperhidrosis of the upper limbs. Ann. Surg. 220:1 (1994): 86-90.
Shachor D et al. Endoscopic transthoracic sympathectomy in the treatment of primary hyperhidrosis. Arch Surg 129 (1994): 241-244.
Wang L, Hilliges M, Gajecki M, Marcusson J. Johansson O. No change in skin innervation in patients with palmar hyperhidrosis treated with tap-water iontophoresis. Br J Dermatol 131:5 (1994): 742-743.
Kirschbaum C et al. The ‘Trier Social Stress Test’ – a tool for investigating psychobiological stress responses in a laboratory setting. Neuropsychobiology 28: 1-2 (1993): 76-81.
Reinauer S, Neusser A, Schauf G, Holzle E. Iontophoresis with alternating current and direct current offset (AC/DC iontophoresis): a new approach for the treatment of hyperhidrosis. British Journal of Dermatology 129 (1993): 166-169.
Reinauer S, Schauf G, Holzle E. Ross syndrome: treatment of segmental compensatory hyperhidrosis by a modified iontophoretic device. Journal of the American Academy of Dermatology 28:2 (1993): 308-312.
Sato K et al. Generation and transit pathway of H+ is critical for inhibition of palmar sweating by iontophoresis in water. J Appl Physiol 75:5 (1993): 2258-2264.
Harlow BL, Cramer DW, Bell DA, Welch WR. Perineal exposure to talc and ovarian cancer risk. Obstet Gynecol. 1992 Jul;80(1):19-26.
Black M, Gunn A. The management of Frey's syndrome with aluminum chloride hexahydrate antiperspirant. Annals of the Royal College of Surgeons of England 72 (1990): 49-52.
Goh, C. Aluminum chloride hexahydrate versus palmar hyperhidrosis. International Journal of Dermatology 29: 5 (1990): 368-370.
Laccourreye O, Bonan B, Brasnu D, Laccourreye H. Treatment of Frey's syndrome with topical 2% diphemanil methylsulfate (Prantal®): a double-blind evaluation of 15 patients. Laryngoscope 100 (1990): 651-653.
Lillis P, Coleman W. Liposuction for treatment of axillary hyperhidrosis. Dermatologic Clinics 8:3 (1990): 479-482.
Shen J, Lin G, Li W. A new strategy of iontophoresis for hyperhidrosis. Journal of the American Academy of Dermatology 22:2 (1990): 239-241.
Dahl JC, Glent-Madsen L. Treatment of hyperhidrosis manuum by tap water iontophoresis. Acta Derm Venereol 69 (1989): 346-348.
Sato K, Kang W, Saga K, Sato K. Biology of sweat glands and their disorders. I. Normal sweat gland function. J Am Acad Dermatol 20 (1989): 537-563.
Sato K et al. Biology of sweat glands and their disorders. II. Disorders of sweat gland function. J Am Acad Dermatol 20:5 (1989): 713-726.
Glent-Madsen L, Dahl JC. Axillary hyperhidrosis: local treatment with aluminum-chloride hexahydrate 25% in absolute ethanol with and without supplementary treatment with triethanolamine. Acta Derm Venereol 68 (1988): 87-89.
LeWitt P. Hyperhidrosis and hypothermia responsive to oxybutynin. Neurology 38 (1988): 506-507.
Akins D, Meisenheimer J, Dobson R. Efficacy of the drionic unit in the treatment of hyperhidrosis. Journal of the American Academy of Dermatology 16:4 (1987): 828-832.
Dobson R. Treatment of hyperhidrosis. Arch Dermatol 123 (1987): 883-884.
Holzle E, Alberti N. Long-term efficacy and side effects of tap water iontophoresis of palmoplantar hyperhidrosis - the usefulness of home therapy. Dermatologica 175 (1987): 126-135.
James W, Schoomaker E, Rodman O. Emotional eccrine sweating. Arch Dermatol 123 (1987): 925-929.
Khurana R. Orthostatic hypotension-induced autonomic dysreflexia. Neurology 37 (1987): 1221-1224.
Sato K, Sato F. Sweat secretion by human axillary apoeccrine sweat gland in vitro. Am J Physiol 252 (1987): R181-R187.
Stolman LP. Treatment of excess sweating of the palms by iontophoresis. Arch Dermatol 123 (July 1987): 893-896.
Sloan J, Soltani K. Iontophoresis in dermatology. Journal of the American Academy of Dermatology 15:4 (1986): 671-684.
White JW. Treatment of primary hyperhidrosis. Mayo Clin Proc 61 (1986): 951-956.
Tashjian E, Richter K. The value of propoxyphene hydrochloride (darvon) for the treatment of hyperhidrosis in the spinal cord injured patient: an anecdotal experience and case reports. Paraplegia 23 (1985): 349-353.
Hölzle E, Braun-Falco O. Structural changes in axillary eccrine glands following long-term treatment with aluminum chloride hexahydrate solution. Br J Dermatol 110 (1984): 399-403.
Kuritzky A, Hering R, Goldhammer G, Bechar M. Clonidine treatment in paroxysmal localized hyperhidrosis. Arch Neurol 41 (1984): 1210-1211.
Cramer DW, Welch WR, Scully RE, Wojciechowski CA. Ovarian cancer and talc. A case-controlled study. Cancer 50 (1982): 372-376.
Tkach J. Indomethacin treatment of generalized hyperhidrosis. J Am Acad Dermatol 6:4 (1982): 545.
Hill, AC, et al. Mechanism of action of iontophoresis in the treatment of palmar hyperhidrosis. Cutis 28 (1981): 69-70,72.
Levit F. Treatment of hyperhidrosis by tap water iontophoresis. Cutis 26 (August 1980): 192-194.
Rayner C, Ritchie I, Stark G. Axillary hyperhidrosis, 20% aluminum chloride hexahydrate, and surgery. British Medical Journal 10:280 (1980): 1168.
Juhlin L, Evers H, Broberg F. Inhibition of hyperhidrosis by topical application of a local anesthetic composition. Acta Dermatovener 59:6 (1979): 556-559.
Hays LL. The Frey syndrome: a review and double blind evaluation of the topical use of a new anticholinergic agent. Laryngoscope 88 (1978): 1796-1824.
Brandrup F, Larsen P. Axillary hyperhidrosis: local treatment with aluminum chloride hexahydrate 25% in absolute ethanol. Acta Dermatovener (Stockholm) 58 (1978): 461-465.
Kux M. Thoracic endoscopic sympathectomy in palmar and axillary hyperhidrosis. Arch Surg 113:3 (1978): 264-266. (Abstract)
Scholes K et al. Axillary hyperhidrosis treated with alcoholic solution of aluminum chloride hexahydrate. British Medical Journal 2 (1978): 84-85.
Adar R, Kurchin A, Zweig A, Mozes M. Palmar hyperhidrosis and its surgical treatment: a report of 100 cases. Ann Surg 186:1 (1977): 34-41.
Shrivastava S, Singh G. Tap water iontophoresis in palmo-plantar hyperhidrosis. British Journal of Dermatology 96 (1977): 189-195.
Bergstresser, P, Quero R. Treatment of hyperhidrosis with topical methenamine. International Journal of Dermatology 15 (1976): 452-455.
Cullen S. Topical methenamine therapy for hyperhidrosis. Arch Dermatol 111 (1975): 1158-1160.
Abell E, Morgan K. The treatment of idiopathic hyperhidrosis by glycopyrronium bromide and tap water iontophoresis. British Journal of Dermatology 91 (1974): 87-91.
Grice K, Sattar H, Baker H. Treatment of idiopathic hyperhidrosis with iontophoresis of tap water and poldine methosulphate. Br. J. Derm. 86 (1972): 72-78.
Frankland J, Seville R. The treatment of hyperhidrosis with topical propantheline - a new technique. Br. J. Derm. 85 (1971): 577-581.
Juhlin L, Hansson H. Topical glutaraldehyde for plantar hyperhidrosis. Arch Derm 97 (1968): 327-330.
Levit F. Simple device for treatment of hyperhidrosis by iontophoresis. Arch Derm 98 (1968): 505-507.
Bouman HD, Lentzer EM. The treatment of hyperhidrosis of hands and feet with constant current. Am J Phys Med 31 (1952): 158-169.